Video

Dr. Grünwald on depth of response and efficacy with pembrolizumab/lenvatinib in renal cell carcinoma

Author(s):

Urology Times staff
Conference|ASCO Annual Meeting: Bladder Cancer and RCC

The phase 3 CLEAR trial showed that frontline therapy with pembrolizumab (Keytruda) plus lenvatinib (Lenvima) reduced the risk of death by 34% versus sunitinib (Sutent) in patients with advanced renal cell carcinoma.

In this video, Viktor Grünwald, MD, University Hospital Essen, Germany, discusses an analysis shared at the 2021 ASCO Annual Meeting which explored efficacy in the CLEAR trial according to selected subgroups, as well as the association between depth of response and overall survival. (J Clin Oncol 39, 2021 [suppl 15; abstr 4560])

Related Videos
Helen L. Bernie, DO, MPH, answers a question during a video interview
Team of surgeons | Image Credit: © shefkate - stock.adobe.com
Marah C. Hehemann, MD, answers a question during a video interview
Crop shot of senior man sitting on sofa with doctor during home visit taking notes on clipboard | Image Credit: © DragonImages - stock.adobe.com
Olivia Paulsen answers a question during a video interview
Evan Panken, MD, answers a question during a video interview
Petar Bajic, MD, answers a question during a video interview
Related Content
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
November 14th 2024

TENACIO inflatable penile prosthesis pump fills faster compared with MS pump

Benjamin P. Saylor
"We found that the new TENACIO pump was able to complete tasks faster and more efficiently compared to the older MS pump," says Justin Lee, MD.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Laser and radiofrequency vaginal rejuvenation procedures may be safe, effective
October 21st 2024

Laser and radiofrequency vaginal rejuvenation procedures may be safe, effective

Hannah Clarke
Almost all studies (93.5%) reported an improvement in validated patient-reported outcomes following treatment.
Speaking of Urology: 2023 AUA Highlights
May 12th 2023

Speaking of Urology: 2023 AUA Highlights

Urology Times staff
Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
October 20th 2024

CCH appears safe, efficacious in Peyronie disease with ventral curvature

Benjamin P. Saylor
68.8% of patients had at least a 30% improvement in ventral curvature from baseline.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
October 19th 2024

Satisfaction compared for IPP reservoir placement in prevesical vs ectopic location

Benjamin P. Saylor
“The take-home message…is it doesn't matter whether you put the reservoir in the ectopic location or the prevesical location. Patients tend to be satisfied in both locations,” said Mohit Khera, MD, MBA, MPH.
© 2024 MJH Life Sciences

All rights reserved.